C4 Therapeutics, Inc. (NasdaqGS: CCCC)
Health Care · Biotechnology · US
$4.10
+2.50% today · +62.1% 1Y
C4 Therapeutics, Inc. (NasdaqGS: CCCC) operates in the Biotechnology industry within the Health Care sector. The company is valued at $504.40M and employs 104 people.
Over the last twelve months the share price has gained 62.1%, trading between 1.69 and 5.17.
Tweenvest scores C4 Therapeutics, Inc. across four factors: quality 30/100, value 59/100, growth 12/100. Its strongest factor is value.
CCCC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $504.40M
- Revenue (TTM)
- $35.04M
- P/E
- —
- EPS
- -0.91
- Dividend yield
- —
- Beta (5Y)
- 2.95
- 52-week high
- $5.17
- 52-week low
- $1.69
- Avg volume (3M)
- —
- Shares outstanding
- 123.03M
- Employees
- 104
- Next earnings
- —
About C4 Therapeutics, Inc.
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses. The company's primary drug candidate, CFT7455, is an orally administered MonoDAC degrader of the IKZF1 and IKZF3 proteins. This compound is currently undergoing Phase 1/2 clinical trials for the treatment of multiple myeloma and various non-Hodgkin lymphomas, such as peripheral T-cell lymphoma and mantle cell lymphoma. Additionally, C4 Therapeutics is advancing several other programs: CFT8634, an orally bioavailable BiDAC degrader targeting the BRD9 protein, for potential use in synovial sarcoma and SMARCB1-deleted solid tumors. CFT1946, an orally administered BiDAC degrader designed to act on the V600X mutant BRAF, aimed at indications like melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies. CFT8919, an orally available, allosteric, and mutant-selective BiDAC degrader specifically targeting epidermal growth factor receptor (EGFR) with an L858R mutation in NSCLC. Their early-stage pipeline also features RET degraders for various forms of cancer. C4 Therapeutics, Inc. has formed strategic partnerships with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Biogen MA, Inc., and Calico Life Sciences LLC. The company was established in 2015 and its headquarters are located in Watertown, Massachusetts.
- ISIN
- US12529R1077
- Founded
- 2015
- Listed since
- Oct 2, 2020
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €875.40 | +1.30% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $141.70 | +2.02% |
Figures last refreshed Aug 18, 2026.